The company intends to use the funds for the preclinical development of its platform and investigational therapy for kidney and other age-related diseases.Led by Matthew Scholz, chief executive officer and co-founder, Oisín is a late preclinical stage company developing therapeutics to reduce the effects of the aging process. The company’s first therapies target senescent cells using its proprietary technology platform, SENSOlytics. Its DNA-based interventions are designed to clear senescent cells, which can trigger aging pathologies and shorten lifespan, from the body. Oisín expects the first readouts from its preclinical study in CKD, OB-001, later this year. The initial data will inform its next series of studies and eventually, its first proposed clinical trial design. While using this latest funding to accelerate its CKD work, the company is continuing to progress other planned studies in its preclinical program, advance additional pipeline indications and move towards a regulatory filing to begin its first clinical trial.27/05/2021
